All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
October 2024: Cytisine and varenicline added to formulary
News
October 2024: Cytisine and varenicline added to formulary
Cytisine (cytisinicline) 1.5mg tablets have been added to the formulary as a green (first line) option for smoking cessation in adults (aged 18-65 years), as part of a programme of behavioural support.
- To optimise the results from smoking cessation programmes it is advised that patients access motivational support from specialist services.
- Cytisine is taken in a reducing regimen over 25 days.
- Do not offer cytisine to pregnant or breastfeeding women.
- Women of childbearing potential must use highly effective contraception during treatment (refer to formulary entry for additional information). Specialist smoking cessation services should ensure that highly effective contraception is in place and that the GP is informed of this when recommending cytisine.
Varenicline 500micrograms and 1mg tablets have been reclassified as a green (first line) option for smoking cessation in adults, as part of a programme of behavioural support.
- To optimise the results from smoking cessation programmes it is advised that patients access motivational support from specialist services.
- Generic varenicline tablets are now available following stock shortages and discontinuation of the brand (Champix).
- Do not offer varenicline to pregnant or breastfeeding women.
See here for the formulary entry.
